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a b s t r a c t
Advances in the engineering of surgically implanted, durable left ventricular assist devices (LVAD) has led to improvements in the two-year survival of patients on LVAD support, which is now comparable to that of heart
transplant (HT) recipients. And with the advent of magnetic levitation technology, both the survival rate and average time on LVAD support are expected to improve even further. However, despite these advances, the functional capacity of patients on LVAD support remains reduced compared to those who received a HT. A few
small clinical trials have shown improvement in functional capacity with exercise training. Peak oxygen uptake
improves modestly (10%–20%) with exercise training, suggesting a possible celling-effect linked to the ability of
the LVAD to increase ﬂow during exercise. This paper reviews both (a) the effect of the LVAD on the cardiorespiratory responses during a single, acute bout of exercise up to maximum and (b) the central and peripheral adaptations that occur among patients with an LVAD who undergo an exercise training regimen. We also address the
tenets of the exercise prescription that are unique to patients with a durable LVAD.
© 2021 Elsevier Inc. All rights reserved.
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Durable left ventricular (LV) assist device (LVAD) support is indicated for carefully selected individuals with advanced systolic heart failure (HF) refractory to medical optimization (American Heart
Association/American College of Cardiology Stage D systolic heart
failure).1 To date, over 28,000 individuals have undergone Food and

Abbreviations: 6MWT, six minute walk test; BP, blood pressure; CO, cardiac output;
CR, cardiac rehabilitation; FDA, Food and Drug Administration; HF, heart failure; HFrEF,
heart failure with reduced left ventricular ejection fraction; HR, heart rate; HT, heart
transplant; LV, left ventricle; LVAD, Left ventricular assist device; MCS, mechanical
circulatory support; RV, right ventricle; VO2, oxygen uptake.
⁎ Corresponding author at: 6525 Second Avenue, Detroit, MI 48202, USA.
E-mail address: dkerrig1@hfhs.org (D.J. Kerrigan).
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Drug Administration (FDA) approved LVAD implanted in the United
States, as either a bridge to heart transplantation (HT) or for permanent
(“Destination Therapy”) support.2 Currently, durable LV mechanical circulatory support (MCS) improves cardiac output (CO) and perfusion to
vital organs using an electronically powered, continuous ﬂow pump
that removes blood from the LV via an inﬂow cannula, imparts kinetic
energy as the blood traverses a motor, and then expels it through an
outﬂow graft into the patient's ascending aorta (Fig. 1). Phasic blood delivery occurs during both the systolic and diastolic periods of the cardiac
cycle, by means of either an axial (HeartMate II, Abbott, Inc) or centrifugal (HVAD, Medtronic, Inc.; HeartMate 3, Abbott, Inc) ﬂow pathway
within the pump casing. The early generation, FDA approved devices
(HeartMate II and HVAD) were plagued by complications, including

https://doi.org/10.1016/j.pcad.2021.12.002
0033-0620/© 2021 Elsevier Inc. All rights reserved.
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LV, increasing in a linear fashion during higher intensity aerobic-typeexercise (i.e., >50% peak oxygen uptake, VO2).9 In patients on LVAD
support, augmentation of pump ﬂow during exercise is reliant on native
heart contractility and LVAD ﬂow is only moderately correlated to HR
during exercise.10 This observation was reported by Muthiah et al.,
who showed that the contribution of various paced HRs on LVAD ﬂow
rate was negligible.10 This suggests that among patients with an LVAD,
it is likely that other factors have a greater impact on exercise capacity
than chronotropic response.11,12 Right heart dysfunction and pulmonary hypertension, for example, can critically limit LVAD output during
exercise due to impairment in rapid LVAD ﬁlling. Additionally, many patients on continuous ﬂow LVAD support have acquired aortic valve stenosis and/or complete aortic valve leaﬂet fusion (i.e., acquired aortic
valve closure), preventing an increase in native CO via the aortic valve,
and/or aortic insufﬁciency (AI) which leads to ineffective pump ﬂow
due to recirculation.13 If systemic blood pressure (BP) substantially increases during exercise, the gradient driving this recirculation is increased, potentially contributing to exertional intolerance in the LVAD
patient with AI.
Pump speed has a proportional relationship to pump ﬂow, leading
many to speculate about increasing speed as a method to bolster VO2
peak.14–16 However, there are limitations when increasing LVAD speed
with respect to initiating potential RV complications. Additionally, exercise testing studies that adjusted pump speed have not consistently
found improvements in peak VO2, suggesting there are still other
factors inﬂuencing peak VO2.17 Thus, since pump speed is ﬁxed in
contemporary LVADs, the largest contributor to pump ﬂow both at
rest and during exercise is the pressure gradient across the pump
(i.e., pump head or differential pressure). The two main determinates
affecting the pressure gradient across the pump are (a) systemic arterial
BP and (b) LV end diastolic pressure.18,19 Elevation of systemic arterial
BP can lead to a marked reduction in LVAD pump ﬂows in patients on
modern centrifugal ﬂow, continuous LVADs20. During exercise, total peripheral resistance, however, is usually reduced, leading to a subsequent
increase in LVAD output. While this relationship between afterload and
forward ﬂow also happens in the non-LVAD supported native LV, the inﬂuence of afterload is 3–4 times more impactful relative to ﬂow through
the LVAD pump.19 This ﬁnding was shown by Salamonsen et al. who reported that the afterload sensitivity of various continuous ﬂow-LVADs
was 0.09 ± 0.034 L/min/mmHg, compared to the known average values
measured in the human LV of 0.03 ± 0.01 L/min/mmHg21.
With respect to the LV end diastolic pressure during exercise, this is
primarily driven by blood returning to the LV (i.e. preload) through a
combined effect from the skeletal muscle pump and residual RV and
LV contractility.17 The inﬂuence of the skeletal muscle pump on preload
was illustrated during a tilt-table study that found active ankle ﬂexion in
patients on LVAD support increased LVAD ﬂow rate regardless of body
position (i.e., supine versus upright).10 Patient volume status also modulates LV end diastolic pressure, and LVAD ﬂows can markedly drop
when patients with centrifugal ﬂow LVADs (HeartMate 3 and HVAD)
are intravascularly volume depleted.

Fig. 1. Factors inﬂuencing exercise capacity in patients with a left ventricular assist device.

pump thrombosis and strokes, with average survival rates of 84% at
1 year and 46% at 5 years following implant. These early generation
pumps were replaced by third generation HeartMate 3 (Abbott, Inc)
continuous ﬂow technology that uses magnetic levitation to move impellers within a pump housing that is located external to the pericardium. Clinical trial and registry data of patients on HeartMate 3 LVAD
support demonstrate average survival rates of 88% at 1 year and 84%
at 2 years, effectively mirroring that of HT over the short term.3,4 The
HeartMate 3 pump design has effectively eliminated pump thrombosis,
reduced risk for stroke, and is expected to allow for an average survival
time well beyond 5 years.5
Given the improvements in LVAD survival and the increased use of
LVADs in the United States, the number of patients on LVAD support referred for exercise-based cardiac rehabilitation (CR) has commensurately increased. However, despite HF with reduced LV ejection
fraction (HFrEF) representing a diagnosis covered by Medicare, in
2016 only 42% of eligible LVAD patients attended CR.6 One potential barrier to CR in the LVAD patient population is the medical complexity of
these patients, including difﬁculties with the monitoring of vital signs,
equipment management, and small increases in the risk of complications (e.g., arrhythmias, hypotension) during exercise. Additionally, a
survey of European CR facilities cited a lack of properly trained staff
and staff safety concerns as two other reasons why patients on LVAD
support are not enrolled into their CR facility.7 It is likely that the
above concerns, coupled with the complex interaction between the
LVAD and the native cardiovascular system during exercise, both contribute to staff hesitancy and low enrollment into CR. In this paper we
address the exercise physiology of the LVAD patient to a single bout of
exercise, the central and peripheral of adaptations to an exercise training regimen, and how to establish an effective exercise prescription
that mitigates potential safety concerns in these unique patients.
The exercise physiology of the LVAD
Continuous ﬂow LVADs provide resting ﬂow rates of 3–6 L/min,
peaking at ~10 L/min with exercise.8 Present FDA approved continuous
ﬂow LVADs operate at a ﬁxed speed, independent of rest or exercise.8
Therefore, any increase in ﬂow through the pump or through the aortic
valve is dependent on augmentation of native right and left heart function. Durable LVAD technology is typically set at a speed (measured in
revolutions per minute) that can provide adequate end organ perfusion
at rest that is indexed to body surface to yield a ﬂow rate of 2.2–2.4 mL/
min/m2. This approach results in an appropriate unloading of the LV and
does so without adverse impact on the neighboring right ventricle (RV)
or instigation of LV suction.
Despite the discordance between the device and the body's native
CV system, LVAD ﬂow does increase with exercise but via mechanisms
that differ from that of a healthy control (Figure 1). In patients without
LVAD support, heart rate (HR) is a main determinate of CO in the native

The exercise physiology of the native LV acting in concert with LVAD
support
Adding to the complexity of the response of the LVAD during exercise is the contribution of the native LV during exercise. Speciﬁcally, residual contraction of the native LV contributes to pump ﬂow in a
variable manner, both at rest and during exercise. Residual LV contraction leads to increased LV ﬁlling pressures, which peaks during systole,
resulting in LVAD ﬂow rates during systole that are 3 times higher than
during diastole.8
If LV pressure exceeds aortic pressure during systole, aortic valve
opening will occur in LVAD patients without fused/stenotic aortic
valves. In this scenario, the LVAD works in parallel with the native
heart, contributing up to an additional 3 L/min of CO from the native
2
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90
N/A

350
36

55 ± 9

63 ± 10

62 ± 12

Leibner et al. (2013)

Rosenbaum et al. (2018)

Slaughter (2009)

50 HM II

30–90
N/A

21 HM II
4 HVAD
43 HM II
6 HVAD

60 ± 12
59 ± 12
52 ± 2
Cowger et al. (2018)
Cowger et al. (2018)
Gallastegi et al. (2020)

180
180
109
N/A
N/A
29
135 HM 3
127 HM II
25 HVAD
5 HM 3

56 + 12
Benton et al. (2015)

Abbreviations: 6MWT, six-minute walk test; HMII, Heart Mate II; HM3, Heart Mate 3; HVAD, Heart Ware; pVO2, peak oxygen uptake; %pVO2, Percent predicted peak oxygen uptake; VE/VCO2, Slope of the ratio of minute ventilation to carbon dioxide
production. Bold values indicate a p value < 0.05

0.009
0.010
<0.0001
<0.0001
0.001
0.003
<0.001
<0.05
<0.05
0.26
0.02
0.001
<0.001
<0.0001
pVO2 = 15.4 ± 3.9 mL/kg/min %
pVO2 = 54%
6 MW = 312 (215–407)
6 MW = 358 (259–415)
pVO2 = 12.7 ± 0.61 mL/kg/min
Ex time = 8.9 ± 0.5 min
VE/VCO2 = 40.3 ± 1.3
pVO2 = 13.4 ± 5.5 mL/kg/min
%pVO2 = 44%
pVO2 = 12.4 ± 3.0 mL/kg/min
Ex time = 5.8 min
VE/VCO2 = 36.0 ± 6.3
6 MW = 393 ± 81 m
6MWT = 319 ± 191
178
121
10 HM II

pVO2 = 11.6 ± 5.0 mL/kg/min %
pVO2 = 40%
6 MW = 173 (0–290 m)
6 MW = 39 (0–259 m)
pVO2 = 11.0 ± 0.53 mL/kg/min
Ex time = 7.2 ± 0.6 min
VE/VCO2 = 45.4 ± 1.6
pVO2 = 10.1 ± 3.4 mL/kg/min
%pVO2 = 34%
pVO2 = 11.8 ± 2.9 mL/kg/min
Ex time = 5.1 min
VE/VCO2 = 39.2 ± 6.5
6 MW = 344 ± 77 m
6MWT = 182 ± 140

P Value
Preoperative LVAD Exercise
metrics
Time of testing after LVAD
implant (days)
Time of testing before LVAD
implant (days)
Device
type (n)
Participants
Age
Study

Table 1
Measures of functional capacity and other cardiopulmonary measures before and following LVAD implantation.
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Postoperative LVAD Exercise
metrics

D.J. Kerrigan, J.A. Cowger and S.J. Keteyian

heart (via ejection through the aortic valve).22 Evidence of this parallel
blood ﬂow, which was also reported in ﬁrst generation pulsatile
LVADs, is supported by exercise studies showing CO values that exceed
the known parameters of the device.22–24
In patients with ﬁxed/fused aortic valve leaﬂets or marginal residual
LV contractility, the LVAD continues to work in series with the heart
during exercise. In this scenario, residual isovolumic LV contraction
does not allow for aortic valve opening during exercise, but the pressure
gradient between the LVAD inﬂow and aorta is still reduced, promoting
increased ﬂow through the pump during ventricular systole.
The effect of mechanical LVAD support on exercise capacity
Peak VO2 is an important predictor of survival in patients on LVAD
support.25 A recent analysis found survival cut-off values for risk stratiﬁcation in LVAD patients that are similar to patients with HFrEF (i.e. ≤
12 mL/kg/min on a beta-blocker or ≤ 14 mL/kg/min without a betablocker).25 Despite several studies examining peak VO2 before and
after LVAD implant, uncertainty remains whether continuous ﬂowLVADs alone improve peak exercise capacity (Table 1). In one of the
largest cohorts of patients to perform cardiopulmonary exercise testing
before and after LVAD implant (n = 49), Rosenbaum et al. reported a
non-signiﬁcant increase in peak VO2 of 0.6 mL/kg/min (p = 0.26) at
12 months following implant.26 While clinically and/or statistically
signiﬁcant increases in peak VO2 were not observed, signiﬁcant
improvements in peak exercise time (+0.7 min), six-minute walk test
(6MWT) distance (+49 m), and ventilatory efﬁciency [minute ventilation / volume of carbon dioxide expired slope] were noted. Other
smaller studies have demonstrated signiﬁcant improvements in peak
VO2 after LVAD implant; however, the reported increases were modest
at best17.27,28
One factor likely contributing to persistently low age-predicted peak
VO2 levels is the presence of peripheral maladaptations seen in patients
with advanced HF, such as reduced muscle capillary density, endothelial
dysfunction, myocyte atrophy, and downregulation in aerobic enzyme
activity (e.g., citric synthase, etc.).29–31 Additionally, extended hospitalization before and after LVAD implant (16–20 day postoperative and
20–30 days for total length of stay) can markedly exacerbate deconditioning and lead to delays in starting CR. In fact, a report by Richey
et al. found that the average time to begin CR following LVAD implant
was 140 days, which was 90 days longer than the average delay for patients undergoing coronary artery bypass graft surgery and 74 days longer than observed for HT patients.6 Serial exercise testing after LVAD
implant suggests there may be a small increase in peak VO2 within the
ﬁrst few months following LVAD implantation, but over a longer period
peak VO2 remains relatively unchanged.32–34 Therefore, important
implications arise relative to the potential role for exercise training in
helping partially restore peak VO2 and other measures of functional
capacity.
Measures of submaximal functional capacity after LVAD implant
Despite the mixed results for improvement in peak VO2 after LVAD,
improvements in submaximal measures of exercise tolerance and quality of life have consistently been noted in clinical trials.35–38 In a recent
clinical trial of patients on HM3 LVAD support, average 6 MWT distance
increased by 94 m by 6 months postoperative.37
One challenge with such comparisons is that many patients are simply unable to perform any assessment of exercise tolerance or functional capacity just prior to LVAD implant. This limitation was
illustrated by Rogers et al. (2010) and Cowger et al. (2018), both of
which utilized 6MWT distance to measure functional improvements.
In these two studies, if a patient was unable to perform a 6MWT prior
to LVAD implant, they were assigned a 6MWT distance of zero at
baseline, thus potentially inﬂating the magnitude of improvement in
functional capacity after LVAD implant. However, because the vast
3
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reduced hospital length of stay in patients hospitalized for LVAD
implantation.46,47 Despite the positive associations between strength
and outcomes, resistance training studies in this patient population
are sparse. The few exercise training studies that did incorporate resistance exercises did not report any issues and reported improvements
in muscular strength and endurance similar to other HF patients.32,34,40
To our knowledge there has not been a comparison study between aerobic exercise training and strength training.

majority of LVAD patients are intensive care unit conﬁned prior to LVAD
implant due to various degrees of cardiogenic shock, it is likely that the
gains noted in 6MWT distance following LVAD implant are clinically relevant.
The effects of exercise training in patients with LVAD support
While limited by a small number of single site trials, aerobic exercise
training does appear to improve peak VO2 by roughly 10%–20% in this
population.32,39–41 Most of the training studies to date that measured
peak VO2 in patients on LVAD support have involved 6–12 weeks of supervised, continuous aerobic-type exercise at a moderate intensity utilizing either cycle ergometers or treadmills (Table 2). A meta-analysis
of 4 randomized trials involving 74 patients on LVAD support reported
improvements in peak VO2 (+1.94 mL/kg/min, 95% CI 0.63–3.26, p =
0.004).42 However, not all training studies in LVAD patients have
noted similar gains in peak VO2. Additionally, some trials reported
improvements in peak VO2 based on paired analysis within the
training groups but found no signiﬁcant change when measured
against a comparison group. This may be a result of small sample
sizes, variable patient phenotypes, or to the timing of the intervention,
which if it occurred shortly after implant, might have masked changes
in peak VO2 unique to exercise training because of improvements
attributable to the LVAD itself. As mentioned earlier, another possibility
as to why peak VO2 has been found not to improve or improve modestly
with training may be due to the limitations of the LVAD, as well as concomitant right heart dysfunction.
However, despite absent or modest improvements in peak VO2
following exercise training, gains in muscular strength, quality of life,
and improvements in measures of submaximal exercise have been
noted in LVAD patients who have entered exercise training programs
(Table 2). A qualitative meta-analysis of three randomized exercise
training trials showed an average 60 m increase in the 6MWT (95% CI,
22.61–97.50, P = 0.002) following training43 with or without improvements in peak VO2.34,36,39 In a prospective, non-randomized trial of patients on long-term LVAD support (i.e. time on LVAD support
~18 months), Villela et al. reported no change in peak VO2 but a
signiﬁcant improvement in VO2 at ventilatory threshold [7.1 (6.5, 9.1)
to 8.5 (7.7, 9.3) mL/kg/min, P = 0.04] following 5 weeks of higher
intensity interval training.36 Similarly, in a long-term study of LVAD patients who participated in CR, Marko et al. also showed improvements
in ventilatory threshold (5%) and time to exhaustion (33%) despite the
absence of any signiﬁcant change in peak VO2.34
Patient reported health outcomes has also improved with exercise
training and such changes are independently associated with clinical
outcomes. And while there are many reports showing improvement in
these measures following LVAD implantation alone, there is evidence
that exercise training further improves patient reported health outcomes. In a randomized trial comparing usual care to 18 visits in CR
(i.e., 3 days/wk. for 6 weeks), the CR group reported improved scores
on the Kansas City Cardiomyopathy Questionnaire (mean increase =
14.4 points compared to no change in the usual care group).39 Laoutaris
et al. found similar improvements using the Minnesota Living with
Heart Failure Questionnaire, while a training study by Karapolat et al. reported reductions in symptoms of depression in patients with LVADs as
measured by the Beck depression questionnaire, showing an average
improvement from 11.3 ± 7.4 to 5.0 ± 6.0.44 What is presently unknown about these improvements in patient reported health outcomes,
is if a particular exercise mode or intensity of exercise modiﬁes or accentuates the response. Additionally, presently unknown is the inﬂuence
that social support, such as occurs in CR, has on patient reported outcomes.
Muscular strength, which is a known correlate to patient reported
health outcomes and disability, is also associated with improved KCCQ
scores in patients on LVAD support.38,45 In addition, muscular strength
(as measured by a hand grip test) was found to be associated with

Prescribing exercise in patients with LVAD support
Based on the above training studies, exercise seems to be well tolerated and safe in patients on LVAD support. While many exercise trials in
the LVAD population have not disclosed adverse effects, those that have,
report very few untoward events.39,41 Examples of these is a study by
Karapolat et al. that reported only 1 occurrence (i.e., non-sustained ventricular tachycardia) in over 1600 exercise hours and another study by
Kerrigan et al., reporting a single syncopal episode after exercise out of
313 training sessions.39,41
The training stimulus needed to improve functional capacity appears
to be the same as patients with HFrEF not on LVAD support. Thus, performing aerobic exercise 3–5 days/week, for 20–60 min, at intensities
starting as low as 40% of peak VO2 reserve (depending on exercise
capacity) and gradually progressing up to 80% peak VO2 reserve
would be appropriate for patients on LVAD support. Heart rate reserve
(HRR) can be used as a surrogate measure of peak VO2 reserve to
guide exercise intensity, despite the discordance between the LVAD
and native heart. An exception to this would be in patients who display
chronotropic incompetence or rely on a permanent pacemaker to increase rate.48 For these patients there is a weaker association between
VO2 and HR during exercise; therefore, the use of other methods to
guide intensity such as the Borg rating of perceived exertion (6–20
scale) or the Talk Test method would be more appropriate.48
Resistance training is also recommended for patients on LVAD support, although due to the lack of research, there are no speciﬁc guidelines relative to repetitions, sets, and load (i.e., percent of onerepetition maximal). Studies in non-LVAD populations show that
when compared to aerobic exercise, resistance exercises show a less
pronounced reduction in total peripheral resistance and thus potentially, can negatively impact LVAD ﬂow due to the device's sensitivity
to afterload. Because of this, as well as other unknowns in this population, the resistance or intensity of work (i.e., amount of weight lifted)
is generally conservative. This usually equates to performing resistance
bands or light hand weights that can be done 10–15 repetitions, at an
RPE of 11–13 on the 6–20 scale.
Due to the device itself, there are important precautions to consider
beyond the standard wait of 8–12 weeks following sternotomy and
LVAD implant.49 One of these precautions includes restricting extensive
trunk ﬂexion (e.g., sit-ups, leg lifts), which may disrupt the integrity of
LVAD powerline (aka driveline) at the site where it exists in the skin
(i.e., a risk for infection) or increase intra-abdominal pressure (which
can reduce LVAD ﬂow rate). None of the equipment should be exposed
to high levels of moisture (dampening from sweat is generally okay) or
submersion in water. Another precaution needed for all LVAD patients is
reliable driveline stabilization (e.g., abdominal binder or extensive
driveline skin anchoring) to reduce the risk of trauma where the driveline exits the skin or distally, including entanglement of the driveline on
exercise equipment.50 While it is highly unlikely a patient will experience disconnection of power when power sources are securely fastened
per device instructions for use, severe or repetitive kinking of the power
line can damage wire integrity, leading to rare interruptions in power
supply. Careful attention to fall risk is important for this population
due to the extra weight of the device equipment (i.e., batteries and device controller) which can affect the center of gravity in the LVAD patient. As a result, choosing alternative exercises such as a sit-to-stand
or wall squats, as opposed to a regular squat can help build leg strength
4
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Device type
(n)

Study design

Time following
LVAD implant
(days)

Before training exercise
metrics

After training exercise metrics

Laoutaris et al. (2011)

TG = 38 ± 18
CG = 42 ± 15

4 INCOR
10 pulsatile
LVADs
17 EXCOR
11 BiVAD

Randomized control design. Combined home and
supervised exercise on a cycle ergometer or
treadmill for 45 min 3–5 day/wk.

TG = 198 ± 132
CG = 168 ± 114

TG
pVO2 = 16.8 ± 2.9 mL/kg/min
VT = 12.0 ± 5.6 mL/kg/min
Ex time = 9.7 ± 2.2 min
VE/VCO2 = 40 ± 6.5
6 MW = 462 ± 88 m
CG
pVO2 = 14.9 ± 4.0 mL/kg/min
VT = 12.2 ± 4.4 mL/kg/min
Ex time = 8.0 ± 2.9 min
VE/VCO2 = 41.4 ± 6.5
6 MW = 430 ± 41 m
TG
pVO2 = 10.5 ± 2.3 mL/kg/min
Peak work = 42.0 ± 15.4 W
6 MW = 351 ± 77 m
CG
pVO2 = 12.4 ± 1.7 mL/kg/min
Peak work = 50.4 ± 21.6 W
6 MW = 367 ± 77 m

TG
pVO2 = 14.7 ± 3.6 mL/kg/min

TG
pVO2 = 19.3 ± 4.5 mL/kg/min
VT = 15.1 ± 4.2 mL/kg/min
Ex time = 10.1 ± 1.9 min
VE/VCO2 = 35.9 ± 5.6
6 MW = 527 ± 76
CG
pVO2 = 14.8 ± 4.2 mL/kg/min
VT = 12.9 ± 3.4 mL/kg/min
Ex time = 8.4 ± 2.9 min
VE/VCO2 = 40.2 ± 7.3
6 MW = 448 ± 55 m
TG
pVO2 = 14.8 ± 4.9 mL/kg/min
Peak workload = 74.5
± 31.3 W
6 MW = 531 ± 131 m
CG
pVO2 = 15.3 ± 4.4 mL/kg/min
Peak workload = 79.4
± 45.0 W
6 MW = 489 ± 95 m
TG
pVO2 = 15.1 ± 3.4 mL/kg/min

TG
pVO2 = 13.6 ± 3.3 mL/kg/min
VT = 10.0 ± 2.1 mL/kg/min
Ex time = 7.9 ± 1.6 min
VE/VCO2 = 36.8 ± 8.7
6 MW = 350 ± 65 m
CG
pVO2 = 11.2 ± 2.0 mL/kg/min
VT = 9.1 ± 0.7 mL/kg/min
Ex time = 6.6 ± 2.7 min
VE/VCO2 = 38.8 ± 8.0
6 MW = 337 ± 59 m
TG
pVO2 = 11.3 ± 4.1 mL/kg/min
Peak work = 37.8 ± 17.6 W
VE/VCO2 = 37.8± 7.9

TG
pVO2 = 15.3 ± 4.4 mL/kg/min
VT = 10.9 ± 2.1 mL/kg/min
Ex time = 11.0 ± 2.1 min
VE/VCO2 = 37.8 ± 8.8
6 MW = 402 ± 89 m
CG
pVO2 = 11.8 ± 2.0 mL/kg/min
VT = 9.3 ± 1.0 mL/kg/min
Ex time = 7.4 ± 2.9 min
VE/VCO2 = 37.2 ± 8.4
6 MW = 356 ± 52 m
TG
pVO2 = 14.5 ± 5.2 mL/kg/min
Peak work = 61.5 ± 24.6 W
VE/VCO2 = 33.7± 5.8

TG
pVO2 = 12.3 ± 3.2 mL/kg/min
Peak work = 55.7 ± 24.5 W
TG
pVO2 = 11.9 (9.5–14.8) mL/kg/min
VT = 7.1 (6.5–9.1) mL/kg/min
Peak work = 99 (25–141) Watts
VE/VCO2 = 40 (35–44)

TG
pVO2 = 12.2 ± 4.0 mL/kg/min
Peak work = 82.9 ± 26.2 W
TG
pVO2 = 12.0 (10–15)
mL/kg/min
VT = 8.5 (7.7–9.3) mL/kg/min
Peak work = 100 (67–124) Watts
VE/VCO2 = 42 (37–43)

Hayes et al. (2012)

47 ± 15

14 VentrAssist

Karapolat et al. (2013) 46 ± 14;

3 EXCOR
8 HVAD

Kerrigan et al. (2014)

20 HM II
6 HVAD

Marko et al. (2015)

Marko et al. (2017)

Villela et al. (2021)

TG = 53 ± 13
CG = 60 ± 12

TG = 55 ± 12

TG = 57 ± 9;

TG = 51
(29–71)

9 HM II
32 HVAD

7 HM II
8 HVAD
12 HM II
3 HM 3

Randomized control design. Supervised training,
8 weeks on a cycle ergometer and treadmill for
30 min, 3 days/wk. 6 strength training exercises

Combined TG and
CG = 32

Retrospective study. 8-week training period. 90 mins,
TG = 84 ± 64
3 days/wk. using various aerobic modalities and
8 upper and lower body resistance exercise.
Aerobic exercise was at 60%–70% peak VO2
Randomized control design. Supervised training, six weeks TG = 91 ± 33
CG = 73 ± 32
30 mins, 3 days/wk. of stationary cycling, treadmill, or
recumbent stepper. Aerobic exercise was at 60% heart rate
reserve.

Retrospective analysis.
~32 Cardiac rehabilitation sessions using a
combination of stationary cycling and free
walking at an RPE of 13 on the Borg scale.
Lower extremity strength training 2 sets, 12 reps
Retrospective analysis of individuals who participated
in CR twice, separated by over a year.
Training was conducted within of cardiac rehabilitation
Prospective, observational study.
5 wk. Supervised training period, 3 days wk. of high
intensity exercise training on a cycle ergometer. HIIT
protocol: 30 s warm-ups
Six 30-s-high intensity intervals followed by
4-min active recovery.

TG = 48 ± 38

TG = 547 ± 197

TG = 540
(90–1920)

P Value
(within
group)
0.008
0.001
0.3
0.009
0.005
0.5
0.6
0.2
0.9
0.1
<0.05
<0.05
<0.05
<0.05
<0.05
<0.05

<0.05

<0.05
<0.05
<0.05
>0.05
<0.05
>0.05
>0.05
>0.05
>0.05
>0.05
0.007
0.004
0.022

0.906
<0.001
0.6
0.04
0.18
0.88

Abbreviations: 6MWT, six-minute walk test; CG, Control group; EXCOR, extracorporeal; HMII, Heart Mate II; HM3, Heart Mate 3; HVAD, Heart Ware; INCOR, Intracorporeal; LVAD, Left ventricular assist device; pVO2, peak oxygen consumption; %pVO2,
Percent predicted peak oxygen consumption; TG, treatment group; VE/VCO2, Ratio of minute ventilation to carbon dioxide production; RPE, Rating of perceived exertion; VT, Ventilatory threshold. Bold values indicate a p value < 0.05
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Table 2
Measures of functional capacity and other cardiopulmonary measures before and following exercise training in patients with an LVAD.
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6. Ritchey MD, Maresh S, McNeely J, et al. Tracking cardiac rehabilitation participation
and completion among Medicare beneﬁciaries to inform the efforts of a National Initiative. Circ Cardiovasc Qual Outcomes 2020;13, e005902.
7. Ben Gal T, Piepoli MF, Corrà U, et al. Exercise programs for LVAD supported patients:
a snapshot from the ESC afﬁliated countries. Int J Cardiol 2015;201:215-219.
8. Akimoto T, Yamazaki K, Litwak P, et al. Rotary blood pump ﬂow spontaneously increases during exercise under constant pump speed: results of a chronic study.
Artif Organs 1999;23:797-801.
9. American College of Sports Medicine. ACSM’s Guidelines for Exercise Testing and Prescription. Tenth Edition ed. Lippincott Williams & Wilkins. 2018.
10. Muthiah K, Gupta S, Otton J, et al. Body position and activity, but not heart rate, affect
pump ﬂows in patients with continuous-ﬂow left ventricular assist devices. JACC
Heart Fail 2014;2:323-330.
11. Fresiello L, Jacobs S, Timmermans P, et al. Limiting factors of peak and submaximal
exercise capacity in LVAD patients. PLoS One 2020;15, e0235684.
12. Levine BD, Cornwell WK, Drazner MH. Factors inﬂuencing the rate of ﬂow through
continuous-ﬂow left ventricular assist devices at rest and with exercise ∗. JACC:
Heart Fail 2014;2:331-334.
13. Cowger J, Pagani FD, Haft JW, Romano MA, Aaronson KD, Kolias TJ. The development
of aortic insufﬁciency in left ventricular assist device-supported patients. Circ Heart
Fail 2010;3:668-674.
14. Vignati C, Apostolo A, Cattadori G, et al. Lvad pump speed increase is associated with
increased peak exercise cardiac output and vo(2), postponed anaerobic threshold
and improved ventilatory efﬁciency. Int J Cardiol 2017;230:28-32.
15. Jung MH, Hansen PB, Sander K, et al. Effect of increasing pump speed during exercise
on peak oxygen uptake in heart failure patients supported with a continuous-ﬂow
left ventricular assist device. A double-blind randomized study. Eur J Heart Fail
2014;16:403-408.
16. Jung MH, Houston B, Russell SD, Gustafsson F. Pump speed modulations and submaximal exercise tolerance in left ventricular assist device recipients: a doubleblind, randomized trial. J Heart Lung Transpl: Off Public Int Soc Heart Transpl
2017;36:36-41.
17. Fresiello L, Gross C, Jacobs S. Exercise physiology in left ventricular assist device patients: insights from hemodynamic simulations. Ann Cardiothoracic Surg 2021;10:
339-352.
18. Severin R, Sabbahi A, Ozemek C, Phillips S, Arena R. Approaches to improving exercise
capacity in patients with left ventricular assist devices: an area requiring further investigation. Expert Rev Med Dev 2019;16:787-798.
19. Lim HS, Howell N, Ranasinghe A. The physiology of continuous-ﬂow left ventricular
assist devices. J Card Fail 2017;23:169-180.
20. Slaughter MS, Pagani FD, Rogers JG, et al. Clinical management of continuous-ﬂow
left ventricular assist devices in advanced heart failure. J Heart Lung Transpl: Off Public Int Soc Heart Transpl 2010;29:S1-39.
21. Salamonsen RF, Mason DG, Ayre PJ. Response of rotary blood pumps to changes in
preload and afterload at a ﬁxed speed setting are unphysiological when compared
with the natural heart. Artif Organs 2011;35:E47-E53.
22. Jacquet L, Vancaenegem O, Pasquet A, et al. Exercise capacity in patients supported
with rotary blood pumps is improved by a spontaneous increase of pump ﬂow at
constant pump speed and by a rise in native cardiac output. Artif Organs 2011;35:
682-690.
23. Brassard P, Jensen AS, Nordsborg N, et al. Central and peripheral blood ﬂow during
exercise with a continuous-ﬂow left ventricular assist device: constant versus increasing pump speed: a pilot study. Circ Heart Fail 2011;4:554-560.
24. Lai JV, Muthiah K, Robson D, et al. Impact of pump speed on hemodynamics with exercise in continuous ﬂow ventricular assist device patients. ASAIO J (Am Soc Artif Intern Org: 1992) 2020;66:132-138.
25. Mirza KK, Szymanski MK, Schmidt T, et al. Prognostic value of peak oxygen uptake in
patients supported with left ventricular assist devices (PRO-VAD). JACC Heart Fail
2021;10:758-767.
26. Rosenbaum AN, Dunlay SM, Pereira NL, et al. Determinants of improvement in cardiopulmonary exercise testing after left ventricular assist device implantation.
ASAIO J (Am Soc Artif Intern Org: 1992) 2018;64:610-615.
27. Benton CR, Sayer G, Nair AP, et al. Left ventricular assist devices improve functional
class without normalizing peak oxygen consumption. ASAIO J (Am Soc Artif Intern
Org: 1992) 2015;61:237-243.
28. Gallastegi AD, Ozturk P, Demir E, Nalbantgil S, Yagdi T, Ozbaran M. Prospective evaluation of ventricula assist device risk scores capacity to predict cardiopulmonary exercise parameters. Interact Cardiovasc Thorac Surg 2020;30:223-228.
29. Vuckovic KM, Piano MR, Phillips SA. Effects of exercise interventions on peripheral
vascular endothelial vasoreactivity in patients with heart failure with reduced ejection fraction. Heart Lung Circ 2013;22:328-340.
30. Duscha BD, Kraus WE, Keteyian SJ, et al. Capillary density of skeletal muscle: a contributing mechanism for exercise intolerance in class II-III chronic heart failure independent of other peripheral alterations. J Am Coll Cardiol 1999;33:1956-1963.
31. Poole DC, Hirai DM, Copp SW, Musch TI. Muscle oxygen transport and utilization in
heart failure: implications for exercise (in)tolerance. Am J Physiol Heart Circ Physiol
2012;302:H1050-H1063.
32. Hayes K, Leet AS, Bradley SJ, Holland AE. Effects of exercise training on exercise capacity and quality of life in patients with a left ventricular assist device: a preliminary
randomized controlled trial. J Heart Lung Transpl: Off Public Intern Soc Heart Transpl
2012;31:729-734.
33. Leibner E, Cysyk J, Eleuteri K, El-Banayosy A, Boehmer J, Pae W. Changes in the functional status measures of heart failure patients with mechanical assist devices. ASAIO
J 2013;59:117-122.

while reducing the risk of falls. Finally, extended cool down periods and
hydration during recovery are recommended to avoid provocation of
hypotension, dizziness/orthostasis, or device low ﬂow alarms related
to BP dysregulation or dehydration. All patients should have an emergency bracelet or their LVAD labeled with clear information to contact
their physician or LVAD coordinator for questions or urgencies that
may arise.
Future considerations addressing exercise in patients on LVAD support
Exercise training has been shown to have short-term beneﬁts for
patients on LVAD support. As LVAD technology and outcomes continue to improve and the number of patients on long-term MCS increases, there will be more opportunities to look at the long-term
effects of regular exercise on both patient-centered outcomes and
LVAD function. Additionally, there is a need to examine the effects
of CR participation and clinical outcomes in these patients; although
a retrospective analysis by Bachmann et al. showed participation in
CR was associated with a 23% lower adjusted one-year hospitalization risk (95% CI 11%–33%, p < 0.001) and a 47% lower adjusted
one-year mortality risk (95% CI 18%–66%, p < 0.01), a data deﬁcit remains relative to the impact of CR on risks for hospitalization and/or
mortality51 in patients with an LVAD.
In addition to exploring more potential beneﬁts of exercise for patients on LVAD support, there is also a need to reduce common exercise
barriers. The delivery of home-based CR is an opportunity to circumvent
a common barrier to exercise in this population. In a non-randomized
trial by Kugler et al. patients on continuous ﬂow LVADs were given
cycle-ergometers and asked to follow a home-based exercise and nutrition program with telephone follow-ups.52 Compared with a usual care
control group, the home-based exercise group showed improvements
in both predicted peak workload and percent predicted peak VO2.52 At
minimum, this study demonstrated the feasibility of performing a
home-based model in this population and with the recent expansion
of telehealth strategies due the COVID pandemic, the capabilities to provide additional virtual methods of CR continue to expand.
Another important ﬁnding from the study by Kugler et al. was the attenuation of body mass index in the exercise group, while the control
group reported 5-unit increase. This is important and an untapped
area of research, because many studies report substantial increases in
body mass index following LVAD implant, which can effect transplant
status and potentially lead to further complications.53 The above illustrates yet another need and opportunity to provide exercise and lifestyle interventions in the LVAD population. Future interventions will
need to take into account the uniqueness of the LVAD population, considering both the interaction between the device and human physiology
and the speciﬁc needs and characteristics of the patient supported by it.
Lastly, as the LVAD technology evolves so must the exercise and lifestyle
strategies used to improve the health and well-being of these patients.
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